NEW YORK – Adaptive Biotechnologies today announced a partnership with AbbVie to use next-generation sequencing-based minimal residual disease testing in multiple myeloma drug trials.
Under the terms of the multi-year, global collaboration agreement, AbbVie will use Adaptive's clonoSeq assay to assess MRD status in response to venetoclax across multiple clinical trials. The partners will evaluate the depth and duration of response to venetoclax by using clonoSeq to measure and monitor MRD negativity in treated patients.